Home > Oncology > ASCO GU 2022 > Prostate Cancer > ASCO GU 2022 Highlights Podcast

ASCO GU 2022 Highlights Podcast

Presented by
Dr Rachel Giles, Medicom
ASCO GU 2022

In this episode (21:54 min), Medicom’s correspondent covers 6 presentations from the ASCO’s Genitourinary Cancers Symposium (ASCO GU 2022, or #GU22), which was held as a hybrid event from 17-19 February 2022, in San Francisco, California.

1. Continued enzalutamide + docetaxel offers clinical benefit for patients who progress on enzalutamide

In patients with chemotherapy-naïve metastatic castration-resistant prostate cancer treated with docetaxel plus prednisolone who have progressed on enzalutamide, continuation of enzalutamide plus docetaxel led to a significant improvement of progression-free survival, results from the PRESIDE study show.

2. Darolutamide improves OS in patients with mHSPC

The androgen receptor inhibitor darolutamide in combination with androgen deprivation therapy (ADT) and docetaxel improved overall survival in patients with metastatic hormone-sensitive prostate cancer (mHSPC), results from the ARASENS trial show.

3. High-risk early RCC may benefit from neoadjuvant avelumab plus axitinib

Results of the NeoAvAx trial indicate that the neoadjuvant combination of immune checkpoint inhibitor avelumab plus VEGF inhibitor axitinib has potential for use in patients with high-risk, non-metastatic, clear-cell renal cell carcinoma (RCC).

4. Disease-free survival benefits with adjuvant pembrolizumab in RCC persist with longer follow-up

Updated data from the KEYNOTE-564 trial shows continuous disease-free survival advantage with pembrolizumab versus placebo as neoadjuvant therapy for renal cell carcinoma (RCC). With 33% of events needed, overall survival data are not yet mature; however, the hazard ratio is declining.

5. Atezolizumab does not improve survival in advanced penile cancer trial

The phase 2 PERICLES trial examining atezolizumab with or without radiotherapy in patients with advanced squamous cell carcinoma of the penis missed its primary endpoint of 1-year progression-free survival ≥35%.

6. Rucaparib maintenance therapy extends PFS in platinum-responsive metastatic urothelial carcinoma

Results from the ATLANTIS trial platform indicate that rucaparib could play a role in the maintenance treatment of metastatic urothelial carcinoma with a DNA repair deficiency that has responded to first-line platinum-based chemotherapy.


Enjoy listening!


Copyright ©2022 Medicom Medical Publishers

Posted on